|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:1388-1392
© 2004 The American Association for Thoracic Surgery
Surgery for acquired cardiovascular disease |
a Departments ofDepartment of Surgery, Montreal Heart Institute, Montreal, Quebec, Canada
b Department of Medicine, Montreal Heart Institute, Montreal, Quebec, Canada
Received for publication September 5, 2003; revisions received November 24, 2003; accepted for publication December 11, 2003.
* Address for reprints: Michel Carrier, MD, Department of Surgery, Montreal Heart Institute, 5000 Belanger Street, Montreal, Quebec H1T 1C8, Canada
michel.carrier{at}icm-mhi.org
BACKGROUND: Prosthetic valve thrombosis is a life-threatening complication. We reviewed the incidence, risk factors, and treatment strategies of this rare complication.
METHODS: From February 1981 through January 2001, 5430 valve operations were performed in 4924 patients at the Montreal Heart Institute. Of this cohort, 39 patients presented with prosthetic valve thrombosis and had complete follow-up data obtained from our prospective valve clinic database.
RESULTS: In this series 82% of patients were women, and the mean age was 58 ± 11 years. The underlying pathology involved the mitral valve in 75% of cases. Most prosthetic valve thromboses occurred with mechanical prostheses (95%). The time interval from first valve replacement to prosthetic valve thrombosis was 39 ± 42 months. The most frequent clinical presentation was severe congestive heart failure (44%). On prosthetic valve thrombosis presentation, the international normalized ratio was less than 2.5 in 54%, with inadequate anticoagulation management in 26% and poor compliance in 26%. Eighty-two percent of patients underwent a surgical procedure, consisting of thrombectomy in 47%, mitral valve replacement in 47%, and aortic valve replacement in 6% of patients. The 30-day operative mortality and total in-hospital mortality after prosthetic valve thrombosis were 25% and 41%, respectively. The 10-year actuarial survival after prosthetic valve thrombosis was 46% ± 10%.
CONCLUSION: Inadequate level of anticoagulation is the most important factor involved in the pathogenesis of prosthetic valve thrombosis. The overall mortality rate despite surgical treatment remains high. This study underscores the importance of meticulous surveillance of anticoagulation therapy in patients with prosthetic valves.
This article has been cited by other articles:
![]() |
C. J. Boos and H. J. Marshall Factors in Warfarin Therapy Discontinuation Arch Intern Med, September 22, 2008; 168(17): 1932 - 1932. [Full Text] [PDF] |
||||
![]() |
F. M. Caceres-Loriga Prosthetic valve thrombosis: is it time for a new consensus conference? Eur J Echocardiogr, July 1, 2008; 9(4): 413 - 414. [Full Text] [PDF] |
||||
![]() |
R. W. Emery, A. M. Emery, A. Knutsen, and G. V. Raikar Aortic Valve Replacement with a Mechanical Cardiac Valve Prosthesis Card. Surg. Adult, January 1, 2008; 3(2008): 841 - 856. [Full Text] |
||||
![]() |
P. W. X. Foley, R. Sharma, and P. R Karla Beware of prosthetic valve thrombosis despite therapeutic anticoagulation Emerg. Med. J., March 1, 2007; 24(3): e18 - e18. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Rahimtoola The year in valvular heart disease J. Am. Coll. Cardiol., January 4, 2005; 45(1): 111 - 122. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |